Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Vascular Biogenics (NASDAQ:VBLT) and Corium (NASDAQ:CORI).
Vascular Biogenics (VBLT)
Vascular Biogenics received a Buy rating and a $3 price target from H.C. Wainwright analyst Swayampakula Ramakanth today. The company’s shares closed on Friday at $1.42, close to its 52-week low of $1.40.
Ramakanth commented:
“We are upgrading our rating of VBLT to 12-month price target of $3.00 per share. We derive our price target based on the average of two valuation methods: 1) price-sales multiple analysis applying an 6x multiple to our 2026 sales estimate discounted at 18%; and 2) price-earnings multiple analysis applying an 19x multiple to our 2026 estimated earnings discounted at 18%. 1) clinical; 2) regulatory; 3) commercial; 4) partnership; 5) financial; and 6) intellectual property.”
According to TipRanks.com, Ramakanth is a 3-star analyst with an average return of 2.8% and a 37.9% success rate. Ramakanth covers the Healthcare sector, focusing on stocks such as Diffusion Pharmaceuticals Inc, IntelGenx Technologies, and Trillium Therapeutics.
Vascular Biogenics has an analyst consensus of Hold, with a price target consensus of $3.
See today’s analyst top recommended stocks >>
Corium (CORI)
In a report released today, Oren Livnat from H.C. Wainwright downgraded Corium to Hold, with a price target of $13. The company’s shares closed on Friday at $12.70.
According to TipRanks.com, Livnat is a 3-star analyst with an average return of 3.5% and a 60.3% success rate. Livnat covers the Healthcare sector, focusing on stocks such as Zynerba Pharmaceuticals, Pacira Pharmaceuticals, and Jazz Pharmaceuticals.
Corium has an analyst consensus of Moderate Buy, with a price target consensus of $13.50.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
